FDMT Live signals | Maximize Profits with Getagraph.com

SELL 126537 min ago

@ $27.97

Issued: 14 Feb 2024 @ 15:13

Return: -8.12%

Previous signal: Feb 14 - 13:43

Previous signal: Buy

Return: 2.04 %

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 16:00):

Stats
Today's Volume	397 446
Average Volume	667 403
Market Cap	1.31B
EPS	$0 ( 2024-05-08 )
Next earnings date	( $-0.740 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.96
ATR14	$0.0290 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Bizily Scott	Sell	1 250	Stock Option (Right To Buy)
2024-04-16	Bizily Scott	Sell	500	Stock Option (Right To Buy)
2024-04-16	Bizily Scott	Buy	1 250	Common Stock
2024-04-16	Bizily Scott	Buy	500	Common Stock
2024-04-16	Bizily Scott	Sell	1 750	Common Stock

INSIDER POWER
31.03
Last 99 transactions
Buy: 3 571 023 \| Sell: 1 811 773

Volume Correlation

Long: -0.01 (neutral)

Short: -0.97 (very strong negative)

Signal:(32.69) Neutral

4D Molecular Correlation

10 Most Positive Correlations
FCBP	0.889
RDCM	0.883
KURA	0.876
GNTX	0.873
SANM	0.872
PXLW	0.871
USMC	0.869
LRGE	0.869
ESPO	0.868
FWRG	0.867

10 Most Negative Correlations
DISH	-0.853
RTPY	-0.85
LSAQ	-0.849
MMAT	-0.846
TKLF	-0.843
CSSEP	-0.843
DSWL	-0.841
ISDX	-0.838
GSM	-0.832
ZIONP	-0.827

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

4D Molecular Correlation - Currency/Commodity

0.30
( neutral )

0.01
( neutral )

0.00
( neutral )

0.06
( neutral )

0.21
( neutral )

4D Molecular Financials

Annual	2023
Revenue:	$20.72M
Gross Profit:	$14.97M (72.26 %)
EPS:	$-2.58

FY	2023
Revenue:	$20.72M
Gross Profit:	$14.97M (72.26 %)
EPS:	$-2.58

FY	2022
Revenue:	$3.13M
Gross Profit:	$-751 000 (-24.00 %)
EPS:	$-3.12

FY	2021
Revenue:	$18.04M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-11.09

Financial Reports:

No articles found.

4D Molecular

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.